EN  SV

INVESTOR RELATIONS

Welcome to the Fluicell AB Investor Relations page.

On this page you can find annual reports, news, and other information regarding Fluicell.

Collage of 5 images representing Fluicell products

 

DOCUMENTS

Currently, we only publish our documents in Swedish.

Finansiella rapporterProspektBolagsordningTeaser

Årsstämma 2019Extra bolagsstämma 2019

PRESS RELEASES

Subscribe here to press releases.

05/12/2019Genentech förnyar avtal med Fluicell avseende Dynaflow® ResolveNon regulatorisk
02/12/2019Kallelse till extra bolagsstämma i Fluicell AB (publ)Non regulatorisk
02/12/2019Fluicell genomför riktad emission och emitterar vederlagsfria teckningsoptioner i syfte att öka försäljningstillväxt och takten i utvecklingsarbetetRegulatorisk
26/11/2019Omfattande mediaintresse för Biopixlar® - beskrivs som banbrytande bioprinter med stora medicinska möjligheter och unik design.Non regulatorisk
20/11/2019Fluicell offentliggör delårsrapport för tredje kvartalet 2019Regulatorisk
14/11/2019Fluicell har mottagit köporder från BSYS avseende Dynaflow® Resolve chipNon regulatorisk
06/11/2019Fluicell lanserar Biopixlar®-Banbrytande högteknologisk bioprinter av biologiska vävnaderNon regulatorisk
29/10/2019Ny video från Leslie Vosshall-laboratoriet vid Rockefeller University där BioPen® används för potentiellt livsavgörande forskningNon regulatorisk
22/10/2019Ny patentansökan gällande 3D bioprinting fastställer datum för Biopixlar®-lansering till 6 november 2019Regulatorisk
17/09/2019Fluicell har mottagit köporder på BioPen System från The Children’s Hospital of PhiladelphiaNon regulatorisk
21/08/2019Fluicell offentliggör delårsrapport för andra kvartalet 2019Regulatorisk
30/07/2019Fluicell har mottagit köporder på BioPen System från University of GrazNon regulatorisk
18/07/2019Fluicell utser Scientific Advisory BoardNon regulatorisk
19/06/2019Fluicell har mottagit köporder på BioPen System från Cambridge UniversityNon regulatorisk
11/06/2019Fluicell har ingått avtal om överföring av material med Kungliga Tekniska Högskolan KTHNon regulatorisk
25/05/2019Fluicell utökar sitt samarbete med distributionspartnern NPI ElectronicNon regulatorisk
15/05/2019Fluicell offentliggör delårsrapport för första kvartalet 2019Regulatorisk
08/05/2018Kommuniké från dagens årsstämmaRegulatorisk
08/04/2019Kallelse till årsstämma i Fluicell AB (publ)Regulatorisk
02/04/2019Fluicell säljer BioPen System till Rockefeller UniversityNon regulatorisk
28/03/2019Fluicell singerar första betatestningsavtalet för Biopixlar med Cellectricon ABRegulatorisk
15/02/2019Fluicell offentliggör bokslutskommuniké för 2018Regulatorisk
11/12/2018Fluicells BioPen har använts i ny vetenskaplig artikel i prestigefyllda tidskriften Science SignalingNon regulatorisk
21/11/2018Fluicells delårsrapport för januari-september 2018Regulatorisk
19/11/2018Fluicell presenterar sjukdomsrelevant vävnadsbildning från bioprintplattformen Biopixlar på 2nd Annual Drug Development SummitRegulatorisk
16/11/2018Fluicell tecknar nytt avtal och utökar samarbetet med distributionspartnern ScientificaRegulatorisk
13/11/2018Fluicell lanserar ny version av mjukvaran till BioPen-plattformenNon regulatorisk
26/10/2018Fluicell får kritiskt patent beviljat i Europa för BioPen och BiopixlarNon regulatorisk
22/10/2018Universitet i Oslo köper fler spetspipetter till BioPen PRIME-systemNon regulatorisk
12/10/2018Fluicells Dynaflow Resolve-chip köps in av prestigefyllda Oxfords universitetNon regulatorisk
10/10/2018Fluicell installerar det första BioPen PRIME-systemet i IsraelNon regulatorisk
29/08/2018Fluicell släpper Biopixlar® produktdesignRegulatorisk
17/08/2018Fluicells delårsrapport för januari-juni 2018Regulatorisk
04/06/2018Fluicell lanserar BioPen på ny marknad genom exklusivt distributionsavtal i IsraelRegulatorisk
01/06/2018Fluicell Tecknar Ytterligare Distributionsavtal för BioPen System i KinaNon regulatorisk
30/05/2018Fluicell: Kommuniké från gårdagens årsstämmaRegulatorisk
24/05/2018Nytt samarbetsavtal stärker produktutvecklingen av Biopixlar™ RetinaRegulatorisk
17/05/2018Meddelande om stabiliseringsåtgärder i Fluicell AB (publ) under perioden 18 april – 17 maj 2018 samt avslut av stabiliseringsåtgärderRegulatorisk
09/05/2018 Årsredovisning 2017Regulatorisk
09/05/2018Delårsrapport 1 januari – 31 mars 2018Regulatorisk
08/05/2018Meddelande om stabiliseringsåtgärder i Fluicell AB (publ) under perioden 27 april – 8 maj 2018Regulatorisk
27/04/2018Kallelse till årsstämma i Fluicell AB (publ)Regulatorisk
26/04/2018Meddelande om stabiliseringsåtgärder i Fluicell AB (publ)Regulatorisk
26/04/2018 Fluicell introducerar BioPen®FLEXRegulatorisk
18/04/2018Handeln av Fluicells aktie på Nasdaq First North inleds i dagRegulatorisk
12/04/2018Kompletterande bolagsinformation inför listning på Nasdaq Stockholm First North
04/04/2018Fluicells nyemission om 32,7 MSEK inför planerad notering på Nasdaq Stockholm First North blev kraftigt övertecknad
23/03/2018Publicerade resultat stärker tekniken bakom Biopixlar™ Retina för att skapa patientrelevanta vävnadsmodeller för läkemedelsutveckling och forskning
16/03/2018Idag inleds teckningstiden i Fluicell AB
15/03/2018Fluicell beslutar om nyemission och offentliggör prospekt inför notering på Nasdaq Stockholm First North
14/03/2018Fluicell AB (PUBL) bokslutskommuniké 2017
03/11/2017Fluicell AB has in-licensed the Dynaflow® Resolve secondary ion channel screening platform technology from Cellectricon AB
24/07/2017Fluicell receives a new patent acceptance for the BioPen system
05/07/2017Biotech uppstickaren Fluicell AB skiner I nyemmision som övertecknades till nära 300%
14/06/2017Fluicell receives green light with a new BioPen patent in the USA

MANAGEMENT

  • profile

    Victoire Viannay, Chief Executive Officer

    CEO since 2017.

    Born in 1975.

    Previously the COO of Fluicell AB, Victoire is now the CEO. She holds a PhD in Law from Université Paris II Panthéon/Assas. Former Legal & HR Assistant Manager at Institut Curie, former Project Leader at Chalmers University of Technology, former Chief HR and Legal Officer at PSL Research University, Victoire has more than 10 years of experience in labor laws, human resources and legal management, particularly in the field of scientific research.

    Owns 7,500 shares personally.

  • profile

    Gavin D. M. Jeffries, Chief Technology Officer

    CTO since 2017.

    Born in 1980.

    Currently the CTO of Fluicell AB, Gavin has a PhD in Chemistry from the University of Washington, Seattle. He was Assistant Professor at Chalmers University for 4 years and has published over forty peer reviewed scientific publications, with a total citation count of over a thousand. Entrepreneur/founder of two biotech and optics companies, inventor of multiple patents and technologies, Gavin has a strong background in microfluidics, single-cell analysis and optical platform integration. Gavin has published over forty research articles.

    Owns 50.285 shares personally and 185.000 shares through Jeffries and Associates AB.

  • profile

    Tatsiana Lobovkina, Chief Scientific Officer

    CSO since 2018.

    Born in 1975 .

    Tatsiana is the CSO of Fluicell AB and Assistant Professor at Chalmers University of Technology, Gothenburg. After completing a PhD in chemistry from Chalmers, she completed three years of postdoctoral studies at Stanford University in the USA. With more than 10 years of experience as a research scientist, Tatsiana has a strong background in biophysics and biomimics and has published many scientific publications in international journals.

    Currently doesn't own shares.

  • profile

    Mats Jonasson, Chief Financial Officer

    CFO since 2016.

    Born in 1956.

    Mats is presently the CFO of Fluicell AB via Business Control Partner Norden AB. He studied economy at Gothenburg University, and has, for over 20 years, worked as CFO at companies, such as TiFiC AB and NTEX AB.

    Currently doesn't own shares.

BOARD OF DIRECTORS

  • profile

    Stefan Tilk

    Chairman of the board since 2016.

    Born 1964.

    Stefan Tilk is currently the Vice Chairman and group CEO at NEVS AB. He has a Master’s degree in Engineering Physics from Chalmers University of Technology and studied Business Administration in Barcelona School of Economics. Stefan has extensive experience, leading and developing companies as a CEO, including Geveko AB and Elof Hanson Group. Former Senior Executive Vice President for both Volvo Buses and Volvo Trucks, former Executive Vice President at Coor, Stefan has a strong business development background, skilled in negotiation, business planning, operations management, sales, and international business.
    Owns 30,000 shares through STILK AB.

    Independent in relation to the company and major shareholders.

  • profile

    Owe Orwar

    Board member since 2015.

    Born 1964.

    Owe is the CEO of Oblique Therapeutics and Senior Group Leader at the Karolinska Institute. After completing a PhD in chemistry from Gothenburg University, he completed two years of postdoctoral studies at Stanford University.
    Former Global VP of R&D at Sanofi, former President of R&D at Piramal Healthcare, entrepreneur/founder and inventor of six biotech companies, Owe has over 20 years of experience in the pharma and biotech industry. Holder of more than 75 patents, author of hundreds of research articles, he is a pioneer in the fields of single-cell biology and biophysics with several products on the global market.

    Owns 113.995 shares through Clavis & Vose Invest AB.

    Dependent in relation to the company / Independent in relation to major shareholders.

  • profile

    Gavin D. M. Jeffries

    Board member since 2012.

    Born in 1980.

    Currently the CTO of Fluicell AB, Gavin has a PhD in Chemistry from the University of Washington, Seattle. He was Assistant Professor at Chalmers University for 4 years and has published over forty peer reviewed scientific publications, with a total citation count of over a thousand. Entrepreneur/founder of two biotech and optics companies, inventor of multiple patents and technologies, Gavin has a strong background in microfluidics, single-cell analysis and optical platform integration. Gavin has published over forty research articles.

    Owns 50.285 shares personally and 185.000 shares through Jeffries and Associates AB.

    Dependent in relation to the company / Independent in relation to major shareholders.

  • profile

    Daniel T. Chiu

    Board member since 2017.

    Born 1972.

    Education at Harvard University, Stanford University and UC Berkeley.

    Daniel has been Professor of Chemistry and Bioengineering at the University of Washington since 2006. After graduating from Stanford University, he completed postdoctoral research at Harvard University.
    Scientific Founder of multiple Life Sciences/Biomedical companies across Asia, Europe, and U.S.A Member/Chair of numerous advisory and review panels for government and industry, he is a pioneer in the field of single-cell biology with several products on the global market. Daniel has authored more than 200 scientific publications and is the inventor on over 60 issued patents.

    Owns 30,000 shares personally.

    Independent in relation to the company and major shareholders.

  • profile

    Carl Fhager

    Board member since 2017.

    Born in 1975.

    Master of Laws, University of Gothenburg.

    Carl is an experienced and recognized lawyer at MAQS’ Gothenburg office. He has extensive experience of commercial agreements, including ones relating to cooperation, commission, and purchasing, as well as to terms and conditions. He specializes in sports, media, and the entertainment industry in which he has worked for over ten years, in addition to being the sports director of the football club BK Häcken four years. Considering Carl’s dual legal and managerial background, has led him to assist many boards in an advisory manner, or to join them as a member or a chairman.

    Currently doesn't own shares.

    Independent in relation to the company and major shareholders.

Scientific Advisory Board

  • profile

    Astrid Brodd

    Dr. Astrid Brodd is a licensed physician who studied at the University of Toulouse and at the Sahlgrenska Academy of the University of Gothenburg. She is a board-approved dermatologist since 1993 and started the dermatology clinic at the Carlanderska hospital in 1998. Dr. Astrid Brodd is active at Diagnostiskt Centrum Hud in Gothenburg. She has extensive clinical experience both from work in Sweden and internationally.

  • profile

    Göran Gannedahl

    Dr. Göran Gannedahl is a licensed physician and Ph.D who studied at the Karolinska Institute and the University of Uppsala. He is a board-approved surgeon. Dr. Gannedahl has a vast experience of drug development in different therapeutic areas from leading positions in companies such as Novartis and AstraZeneca. He is the Chief Medical Officer at Oblique Therapeutics in Gothenburg.

  • profile

    Michael Olausson

    Prof. Michael Olausson is a licensed physician and Ph.D who studied at the Sahlgrenska Academy of the university of Gothenburg. He is a board-certified specialist in transplantation surgery. Professor Olausson has been active as a transplantation surgeon at the Sahlgrenska Academy and Sahlgrenska University hospital since 1987. He is the founder and chairman of the Sahlgrenska Transplant Institute and is the author of more than 300 research papers and book chapters. Professor Olausson is a pioneer in the area of transplantation surgery and has introduced and conducted new innovative therapies as first in the world, first in Europe, first in Scandinavia and first in Sweden.

CALENDAR

19/02/2020Bokslutskommuniké 2019
08/05/2020Kvartalsrapport 1, 2020
14/05/2020Årsstämma

INFORMATION ABOUT SHAREHOLDERS

2019/09/30


Owner Name
OwnershipVoting Rights
Quiq Distribution Holding529 4257,07%
Danske Bank International S.A500 0006,68%
Daniel Johnsson432 4365,78%
Carljohan Lagerwall AB428 1005,72%
Danica Pension314 3664,20%
Aldo Jesorka277 8303,71%
Alar Ainla263 0103,51%
Avanza Pension252 9553,38%
Jeffries and Associates AB204 0002,73%
Övriga aktieägare4 282 84857,22%
Totalt 7 484 970100,00%

CERTIFIED ADVISOR

Mangold Fondkommission AB tel. +46 8-503-015-50

 

NASDAQ FIRST NORTH GROWTH MARKET

Nasdaq First North Growth Market is a registered SME growth market, in accordance with the Directive on Markets in Financial Instruments (EU 2014/65) as implemented in the national legislation of Denmark, Finland and Sweden, operated by an exchange within the Nasdaq group. Issuers on Nasdaq First North Growth Market are not subject to all the same rules as issuers on a regulated main market, as defined in EU legislation (as implemented in national law). Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in an issuer on Nasdaq First North Growth Market may therefore be higher than investing in an issuer on the main market. All issuers with shares admitted to trading on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The respective Nasdaq exchange approves the application for admission to trading.